Eli Lilly & Co Ranks 23rd in Trading Volume as FDA Approval Boosts Stock Price

On June 25, 2025, Eli Lilly & Co. (LLY) saw a trading volume of 23.87 billion, ranking 23rd in the day's stock market. The company's stock price rose by 1.83%, marking the third consecutive day of gains, with a total increase of 3.88% over the past three days.

Eli Lilly & Co. announced that the U.S. FDA has approved a label update for Amyvid (florbetapir F 18 injection) for intravenous use. This update supports the diagnosis of Alzheimer's disease in patients, which is expected to enhance the drug's market potential and drive future revenue growth.

The approval of the updated label for Amyvid is a significant milestone for Eli Lilly & Co., as it reinforces the company's commitment to innovation and improving patient outcomes. This development is likely to boost investor confidence in the company's ability to deliver on its strategic goals and maintain its competitive edge in the pharmaceutical industry.